Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.

Autor: Karron RA; Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. rkarron@jhsph.edu, Thumar B, Schappell E, Surman S, Murphy BR, Collins PL, Schmidt AC
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2012 Jun 06; Vol. 30 (26), pp. 3975-81. Date of Electronic Publication: 2011 Dec 14.
DOI: 10.1016/j.vaccine.2011.12.022
Abstrakt: Human parainfluenza virus type 3 (HPIV3) is an important cause of lower respiratory tract illness in children, yet a licensed vaccine or antiviral drug is not available. We evaluated the safety, tolerability, infectivity, and immunogenicity of two intranasal, live-attenuated HPIV3 vaccines, designated rHPIV3-N(B) and rB/HPIV3, that were cDNA-derived chimeras of HPIV3 and bovine PIV3 (BPIV3). These were evaluated in adults, HPIV3 seropositive children, and HPIV3 seronegative children. A total of 112 subjects participated in these studies. Both rB/HPIV3 and rHPIV3-N(B) were highly restricted in replication in adults and seropositive children but readily infected seronegative children, who shed mean peak virus titers of 10(2.8) vs. 10(3.7)pfu/mL, respectively. Although rB/HPIV3 was more restricted in replication in seronegative children than rHPIV3-N(B), it induced significantly higher titers of hemagglutination inhibition (HAI) antibodies against HPIV3. Taken together, these data suggest that the rB/HPIV3 vaccine is the preferred candidate for further clinical development.
(Copyright © 2012. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: